Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prometa L34
- Development stage
- Unknown
- Lead developer
- Greater Pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Prometa L34 is a probiotic dietary supplement containing the indigenous Thai strain *Lactobacillus rhamnosus* L34 (also classified as *Lacticaseibacillus rhamnosus* L34). Developed by Greater Pharma in collaboration with the Faculty of Medicine at Chulalongkorn University, the supplement is designed to support gut and kidney health. *Lactobacillus rhamnosus* L34 is highly tolerant to gastric acid, bile, and capsaicin (the active component in chili peppers), making it particularly suited to the Thai diet. It works by strengthening the intestinal epithelial barrier to prevent leaky gut syndrome, reducing the translocation of gut-derived uremic toxins into the bloodstream, and lowering systemic inflammatory cytokines (such as TNF and IL-8). Prometa L34 is marketed for the management of leaky gut syndrome and to slow the progression of chronic kidney disease (CKD stages 3-5, non-dialysis) by reducing kidney fibrosis and inflammation.
- Brand names
- GREATER Prometa L34PrometaPrometa L34
- Other names
- L34L-34L 34L34 probioticL-34 probioticL 34 probioticLacticaseibacillus rhamnosus L34Lactobacillus rhamnosus L34
02
Targets
IL8 (C-X-C Motif Chemokine Ligand 8)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Prometa L34.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prometa L34.